ReleaseWire

Grunenthal GmbH - Product Pipeline Review - 2014

RuiYi Inc. - Product Pipeline Review - 2014

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014

Botulism - Pipeline Review, H2 2014

ProCertus BioPharm Inc. - Product Pipeline Review - 2014

Global Markets Direct's, 'Medesis Pharma S.A. - Product Pipeline Review - 2014', provides an overview of the Medesis Pharma S.A.'s pharmaceutical research and development focus.

Opsona Therapeutics Ltd. - Product Pipeline Review - 2014

Drais Pharmaceuticals, Inc. - Product Pipeline Review - 2014

AvidBiotics Corp. - Product Pipeline Review - 2014

Rotavirus Infections - Pipeline Review, H2 2014

Febrile Neutropenia - Pipeline Review, H2 2014

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

DelMar Pharmaceuticals, Inc.(OTCQB: DMPI) ("DelMar" “the company”) announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. The company also confirmed that gross proceeds of US$2.9 million have been raised through warrant exercise in two separate closings. These funds provide sufficient working capital to fund DelMar’s current operations, including its glioblastoma clinical trial, through at least December 2015.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular transport between lysosome and other cellular compartments. These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate stored, cell types affected by this storage, and resulting organ involvement. Due to the high variability of these components, the clinical manifestations of even a single disease vary from person to person. These symptoms also vary between members of the same family with identical mutations. The age of onset also varies for lysosomal storage diseases depending on the rate of substrate accumulation. Lysosomal storage diseases are classified on the basis of the substrate being accumulated or on the type of molecular defect associated with the disease. Neuronal ceroid-lipofuscinoses vary from classical lysosomal storage diseases where the component that gets accumulated is mitochondrial ATP synthase subunit C or sphingolipid activator proteins A and D.

ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, has received notification from the Japan Patent Office that a patent for MuGard and ProctiGard has been granted. The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders.

Global Markets Direct's, 'KaloBios Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the KaloBios Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H2 2014', provides an overview of the Endometrial Cancer's therapeutic pipeline.

Global Markets Direct's, 'Santen Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Santen Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Global Markets Direct's, 'Targacept, Inc. - Product Pipeline Review - 2014', provides an overview of the Targacept, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Rexahn Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Rexahn Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'SelectX Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the SelectX Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Oncodesign SA - Product Pipeline Review - 2014', provides an overview of the Oncodesign SA's pharmaceutical research and development focus.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.